Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 10 Jun 2024 16:45:37 +0200Fri, 12 Jan 2024 10:20:00 +0100Libtayo : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4844-en.pdfLibtayo : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4844-en.pdfFri, 12 Jan 2024 10:20:00 +0100Human medicineHuman medicines European public assessment report (EPAR): Libtayo, cemiplimab, Date of authorisation: 28/06/2019, Revision: 16, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/libtayoHuman medicines European public assessment report (EPAR): Libtayo, cemiplimab, Date of authorisation: 28/06/2019, Revision: 16, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/libtayoFri, 12 Jan 2024 09:56:00 +0100Human medicine